Data gathered: November 1
Alternative Data for Petros Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 92 | Sign up | Sign up | Sign up |
| Webpage traffic | 1,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 30 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 7,579 | Sign up | Sign up | Sign up |
| Twitter Mentions | 5 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Petros Pharmaceuticals
Petros Pharmaceuticals, Inc. is dedicated to identifying, acquiring, developing and marketing therapies for men's health problems in the United States and internationally. The company is headquartered in New York, New York.
| Price | $0.37 |
| Target Price | Sign up |
| Volume | 186,980 |
| Market Cap | $3.7M |
| Year Range | $0.3 - $1.72 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Critical Review: Petros Pharmaceuticals (NASDAQ:PTPI) and Protagonist Therapeutics (NASDAQ:PTGX)October 28 - ETF Daily News |
|
Petros Pharmaceuticals (NASDAQ:PTPI) Trading Up 30.4% – Time to Buy?October 21 - ETF Daily News |
Petros Pharmaceuticals Amends President’s Employment TermsOctober 17 - TipRanks |
|
Board Reshuffle at Petros Pharmaceuticals Following ResignationsOctober 3 - TipRanks |
|
|
Petros Pharmaceuticals (NASDAQ:PTPI) Shares Down 2.1%September 24 - ETF Daily News |
 |
Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)September 10 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '24 | 1.5M | 3.3M | 1.1M | -660,000 | -1.6M | -0.370 |
| Q1 '24 | 1.5M | 3.8M | 1.1M | -2.2M | -3.2M | -1.690 |
| Q4 '23 | 6.1M | 3.8M | -520,000 | 320,000 | -4.2M | -2.290 |
| Q3 '23 | 190,000 | 2.4M | 1.3M | -4.5M | -4M | -2.306 |
| Q2 '23 | 1.9M | 2.8M | 1.5M | -2.5M | -1.6M | -1.203 |
Insider Transactions View All
No recorded Insider transactions.
Similar companies
Read more about Petros Pharmaceuticals (PTPI) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions & customer reviews.
What is the Market Cap of Petros Pharmaceuticals?
The Market Cap of Petros Pharmaceuticals is $3.7M.
What is the current stock price of Petros Pharmaceuticals?
Currently, the price of one share of Petros Pharmaceuticals stock is $0.37.
How can I analyze the PTPI stock price chart for investment decisions?
The PTPI stock price chart above provides a comprehensive visual representation of Petros Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Petros Pharmaceuticals shares. Our platform offers an up-to-date PTPI stock price chart, along with technical data analysis and alternative data insights.
Does PTPI offer dividends to its shareholders?
As of our latest update, Petros Pharmaceuticals (PTPI) does not offer dividends to its shareholders. Investors interested in Petros Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Petros Pharmaceuticals?
Some of the similar stocks of Petros Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.